Forgot Password?
Return to Course Listing

CME: Pediatric Growth Hormone Deficiency (PGHD): Therapeutic Updates, Present Clinical Controversies, and Barriers to Care

Activity Description / Statement of Need:

In this online self-learning activity:

 

Growth hormone deficiency (GHD), a condition characterized by inadequate endogenous production, may arise from manifold etiologies such as tumors, radiation, medications, or traumatic brain injury and occurs in about one out of every 4,000 children. The differential diagnosis includes hypothyroidism, Turner syndrome, and familial short stature among others. The most up-to-date guidance on treatment of pediatric GHD has been published relatively recently, and research suggests that healthcare professionals are oftentimes unable to keep up with the steady publishing of literature and evolution of clinical practice.

Target Audience:

The following healthcare professionals: endocrinologists, pediatricians, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in endocrinology; and any other healthcare professionals with an interest in or who clinically encounter patients with GHD.


This program is supported by an educational grant from Novo Nordisk.


Release Date: February 14, 2018 -- Expiration Date: February 14, 2020

Faculty: Michael Yafi, MD

Agenda

A review primer: epidemiologic, pathophysiologic, etiologic features, and clinical signs and symptoms

  • Common ground: definitions, background, statistics
  • Leading abnormalities and causes
  • Comorbidities and complications
  • Clinical pearls and diagnostic practice guidance
  • Patient cases

Treatment options available for GHD

  • 2016 Pediatric Endocrine Society guidelines
  • Pharmacotherapy detailing: review and updates
  • Transition to adulthood
  • Best practices
  • Monitoring parameters, counseling points, barriers to care, and patient education
  • Patient case(s)

 

Learning Objectives

By the end of the session the participant will be able to:

  • Describe the underlying pathophysiological and typical clinical features of pediatric GHD as they pertain to therapeutic targets
  • Describe the optimal approach in diagnosing pediatric GHD and apply it to a patient case
  • Given a patient with pediatric GHD, design a pharmacotherapeutic regimen based on his or her clinical presentation
  • Evaluate patient cases during follow-up visits, including during transition therapy to adulthood when relevant, in a manner that optimizes one or more of the following: efficacy, safety, quality of life, or patient education and adherence
  • Describe best practices in tracking response to pediatric GHD therapy

Accreditation

THIS COURSE HAS EXPIRED. NO CREDIT WILL BE ISSUED FOR COMPLETING IT.

 


Faculty Disclosure and Resolution of COI

 As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

 

Faculty Disclosure: Michael Yafi, M.D., Director, Division of Pediatric Endocrinology, Assistant Professor, The University of Texas - Houston Health Science Center, has no relevent financial disclosures.


Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP has no relevent financial disclosures.

 

Commercial Support Disclosure: This program is supported by an educational grant from Novo Nordisk.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Take the post-test
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

This activity has expired so no certificate is available.


Additional Courses That Are Related To This Activity

The Current and Emerging Landscape of Adult Growth Hormone Deficiency (AGHD) Pharmacotherapy